

# International Myeloma Working Group molecular class spotlight review

Leukemia

23, 2210-2221

DOI: [10.1038/leu.2009.174](https://doi.org/10.1038/leu.2009.174)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Spotlight review series on multiple myeloma. <i>Leukemia</i> , 2009, 23, R1-R2.	3.3	2
2	The Basis and Rational Use of Molecular Genetic Testing in Mature B-cell Lymphomas. <i>Advances in Anatomic Pathology</i> , 2010, 17, 333-358.	2.4	7
3	MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. <i>Blood</i> , 2010, , .	0.6	13
4	CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. <i>Haematologica</i> , 2010, 95, 1542-1547.	1.7	31
7	Austrian consensus recommendations for the treatment of patients with multiple myeloma. <i>Memo - Magazine of European Medical Oncology</i> , 2010, 3, 7-10.	0.3	1
8	Recent advances in bone marrow biopsy pathology. <i>Journal of Hematopathology</i> , 2010, 3, 129-136.	0.2	0
9	Optimization of immunomagnetic selection of myeloma cells from bone marrow using magnetic activated cell sorting. <i>International Journal of Hematology</i> , 2010, 92, 314-319.	0.7	26
11	Epigenetics and MicroRNAs Combine to Modulate the MDM2/p53 Axis in Myeloma. <i>Cancer Cell</i> , 2010, 18, 299-300.	7.7	10
12	Interphase fluorescence in situ hybridization on selected plasma cells is superior in the detection of cytogenetic aberrations in plasma cell dyscrasia. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 991-997.	1.5	11
13	An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era. <i>American Journal of Hematology</i> , 2010, 85, 752-756.	2.0	16
14	Anaplastic plasmacytoma of mouse – establishing parallels between subtypes of mouse and human plasma cell neoplasia. <i>Journal of Pathology</i> , 2010, 221, 242-247.	2.1	3
15	Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. <i>Haematologica</i> , 2010, 95, 1730-1737.	1.7	49
16	Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity. <i>The Application of Clinical Genetics</i> , 2010, 3, 41.	1.4	3
17	A critical role for the NFκB pathway in multiple myeloma. <i>Oncotarget</i> , 2010, 1, 59-68.	0.8	139
18	Plasma cell neoplasms. , 0, , 244-265.		0
19	DNA Methylation Analysis Determines the High Frequency of Genic Hypomethylation and Low Frequency of Hypermethylation Events in Plasma Cell Tumors. <i>Cancer Research</i> , 2010, 70, 6934-6944.	0.4	61
20	Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma. <i>Expert Review of Hematology</i> , 2010, 3, 165-174.	1.0	13
21	Multiple myeloma. <i>Annals of Oncology</i> , 2010, 21, vii143-vii150.	0.6	73

#	ARTICLE	IF	CITATIONS
22	Number of expressed cancer/testis antigens identifies focal adhesion pathway genes as possible targets for multiple myeloma therapy. <i>Leukemia and Lymphoma</i> , 2010, 51, 1543-1549.	0.6	6
23	Ten Years of Improvement in the Management of Multiple Myeloma: 2000-2010. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 424-442.	0.2	26
24	First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Tj ETQq0 0 0 ggBT /Overlock 10 Tf	6.3	505
25	Presentation and risk stratification "improving prognosis for patients with multiple myeloma. <i>Cancer Treatment Reviews</i> , 2010, 36, S12-S17.	3.4	17
26	Optimising bortezomib in newly diagnosed multiple myeloma. <i>Lancet Oncology, The</i> , 2010, 11, 909-910.	5.1	6
27	Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , 2010, 51, 2084-2091.	0.6	34
28	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. <i>Blood</i> , 2011, 117, 5573-5581.	0.6	161
29	Many Multiple Myelomas: Making More of the Molecular Mayhem. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 344-353.	0.9	46
30	Microcalorimetry of Blood Serum Proteome: A Modified Interaction Network in the Multiple Myeloma Case. <i>Analytical Chemistry</i> , 2011, 83, 7992-7998.	3.2	68
31	High-Risk Multiple Myeloma: Does it Still Exist?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S70-S76.	0.2	3
32	Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1916-1923.	0.8	78
33	Clinicopathologic analysis of the impact of CD23 expression in plasma cell myeloma with t(11;14)(q13;q32). <i>Annals of Diagnostic Pathology</i> , 2011, 15, 385-8.	0.6	3
34	The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. <i>Cancer Genetics</i> , 2011, 204, 3-12.	0.2	178
35	Genomic Aberrations and Survival of Patients with Light-Chain-Only Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1790-1795.	2.0	3
36	Pathogenesis of Myeloma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2011, 6, 249-274.	9.6	237
37	Multiple myeloma and the road to personalised medicine. <i>Lancet Oncology, The</i> , 2011, 12, 617-619.	5.1	60
38	Multiple Myeloma: Current Perspectives. <i>Clinics in Laboratory Medicine</i> , 2011, 31, 699-724.	0.7	8
39	Multiple Myeloma. <i>New England Journal of Medicine</i> , 2011, 364, 1046-1060.	13.9	2,109

#	ARTICLE	IF	CITATIONS
40	Pathogenesis of Monoclonal Gammopathy of Undetermined Significance and Progression to Multiple Myeloma. <i>Seminars in Hematology</i> , 2011, 48, 4-12.	1.8	91
41	Myelomagenesis: Capturing Early Microenvironment Changes. <i>Seminars in Hematology</i> , 2011, 48, 13-21.	1.8	7
42	Prognostic significance of morphological assessment of plasma cells in multiple myeloma. <i>Neoplasma</i> , 2011, 58, 554-560.	0.7	6
43	Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. <i>Haematologica</i> , 2011, 96, 1504-1511.	1.7	48
44	Abnormalities in immunoglobulin synthesizing cells. , 2011, , 451-469.		0
45	Molecular Genetics and Cytogenetics in Cancer. <i>Genetics Research International</i> , 2011, 2011, 1-2.	2.0	1
46	MicroRNAs: New Players in Multiple Myeloma. <i>Frontiers in Genetics</i> , 2011, 2, 22.	1.1	37
47	Molecular Characteristics of Mantle Cell Lymphoma Presenting With Clonal Plasma Cell Component. <i>American Journal of Surgical Pathology</i> , 2011, 35, 177-189.	2.1	23
48	A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. <i>Haematologica</i> , 2011, 96, 574-582.	1.7	141
49	Bortezomib-induced $\alpha$ BcrAness $\epsilon$ -sensitizes multiple myeloma cells to PARP inhibitors. <i>Blood</i> , 2011, 118, 6368-6379.	0.6	125
50	Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14). <i>Blood</i> , 2011, 117, 3809-3815.	0.6	60
51	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011, 117, 3025-3031.	0.6	247
52	ABT-737 is highly effective against molecular subgroups of multiple myeloma. <i>Blood</i> , 2011, 118, 3901-3910.	0.6	106
53	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
54	Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone. <i>Blood</i> , 2011, 118, 4359-4362.	0.6	39
55	Approach to the treatment of multiple myeloma: a clash of philosophies. <i>Blood</i> , 2011, 118, 3205-3211.	0.6	137
56	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). <i>Blood</i> , 2011, 118, 4519-4529.	0.6	309
57	N-cadherin-mediated interaction with multiple myeloma cells inhibits osteoblast differentiation. <i>Haematologica</i> , 2011, 96, 1653-1661.	1.7	36

#	ARTICLE	IF	CITATIONS
58	Successful Treatment of Immunoglobulin D Myeloma by Bortezomib and Dexamethasone Therapy. <i>Internal Medicine</i> , 2011, 50, 2653-2657.	0.3	3
59	The Impact of Genomics on the Management of Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1200-1206.	2.3	9
60	Guidelines for the diagnosis and management of multiple myeloma 2011. <i>British Journal of Haematology</i> , 2011, 154, 32-75.	1.2	252
61	Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03. <i>British Journal of Haematology</i> , 2011, 155, 340-348.	1.2	29
62	Correlation of assessment of plasma cells by flow cytometry and detection of cytogenomic abnormalities by fluorescence <i>in situ</i> hybridization in plasma cell neoplasms. <i>International Journal of Laboratory Hematology</i> , 2011, 33, 545-550.	0.7	2
63	4th BBBB International Conference on Pharmaceutical Sciences. <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 1-204.	1.9	32
64	Proteomic Analysis in Multiple Myeloma Research. <i>Molecular Biotechnology</i> , 2011, 47, 83-93.	1.3	15
65	Update on risk stratification and treatment of newly diagnosed multiple myeloma. <i>International Journal of Hematology</i> , 2011, 94, 310-320.	0.7	33
66	Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents. <i>International Journal of Hematology</i> , 2011, 94, 307-309.	0.7	5
67	MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. <i>Biology Direct</i> , 2011, 6, 23.	1.9	87
68	Multiple myeloma: 2011 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2011, 86, 57-65.	2.0	137
69	The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 765-774.	1.5	59
70	International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols. <i>Cancer</i> , 2011, 117, 1001-1009.	2.0	30
71	Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. <i>Cancer</i> , 2011, 117, 2136-2144.	2.0	54
72	Evolutionary sequence of cytogenetic aberrations during the oncogenesis of plasma cell disorders. Direct evidence at single cell level. <i>Leukemia Research</i> , 2011, 35, 1114-1116.	0.4	5
73	Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. <i>Epigenetics</i> , 2011, 6, 1047-1052.	1.3	23
74	The Autism Candidate Gene Neurobeachin Encodes a Scaffolding Protein Implicated in Membrane Trafficking and Signaling. <i>Current Molecular Medicine</i> , 2011, 11, 204-217.	0.6	45
75	Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (< 12 months). <i>Leukemia and Lymphoma</i> , 2011, 52, 34-41.	0.6	45

#	ARTICLE	IF	CITATIONS
76	Genomics in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1234-1242.	3.2	84
77	Plasma Cell Myeloma and Related Neoplasms. <i>American Journal of Clinical Pathology</i> , 2011, 136, 168-182.	0.4	107
78	Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical Routine. <i>Clinical Cancer Research</i> , 2011, 17, 7240-7247.	3.2	43
79	Detection of Genomic Abnormalities in Multiple Myeloma. <i>American Journal of Clinical Pathology</i> , 2011, 136, 712-720.	0.4	33
80	Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients. <i>Annals of Oncology</i> , 2011, 22, 411-416.	0.6	40
81	Disentangling the Myeloma Web. <i>Clinical Cancer Research</i> , 2011, 17, 7210-7212.	3.2	3
82	Genetic Markers Used for Risk Stratification in Multiple Myeloma. <i>Genetics Research International</i> , 2011, 2011, 1-4.	2.0	7
83	Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1703-1707.	1.1	39
84	Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. <i>Annals of Oncology</i> , 2011, 22, 1628-1635.	0.6	65
85	New Recurrent Chromosome Alterations in Patients with Multiple Myeloma and Plasma Cell Leukemia. <i>Cytogenetic and Genome Research</i> , 2011, 134, 249-259.	0.6	4
86	Heterogeneity in the Prognostic Significance of 12p Deletion and Chromosome 5 Amplification in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, e37-e39.	0.8	12
87	Mapping of Chromosome 1p Deletions in Myeloma Identifies <i>FAM46C</i> at 1p12 and <i>CDKN2C</i> at 1p32.3 as Being Genes in Regions Associated with Adverse Survival. <i>Clinical Cancer Research</i> , 2011, 17, 7776-7784.	3.2	147
88	Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. <i>Leukemia</i> , 2011, 25, 749-760.	3.3	108
89	Treatment of multiple myeloma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 479-491.	12.5	239
90	Deciding on the therapy of multiple myeloma using genetic risk stratification. <i>Leukemia and Lymphoma</i> , 2011, 52, 157-158.	0.6	0
92	Frequent <i>PVT1</i> Rearrangement and Novel Chimeric Genes <i>PVT1-NBEA</i> and <i>PVT1-WWOX</i> Occur in Multiple Myeloma with 8q24 Abnormality. <i>Cancer Research</i> , 2012, 72, 4954-4962.	0.4	89
93	Flow Cytometry Method as a Diagnostic Tool for Pleural Fluid Involvement in a Patient with Multiple Myeloma. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2012, 4, e2012063.	0.5	17
94	Flowcytometric evaluation of cell cycle regulators (cyclins and cyclin dependent kinase inhibitors) expressed on bone marrow cells of patients with chronic myelogenous leukemia and multiple myeloma. <i>Turkish Journal of Haematology</i> , 2012, 29, 17-27.	0.2	1

#	ARTICLE	IF	CITATIONS
95	Cancer/Testis Antigen MAGE-C1/CT7: New Target for Multiple Myeloma Therapy. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	30
96	Array-Based Karyotyping in Plasma Cell Neoplasia After Plasma Cell Enrichment Increases Detection of Genomic Aberrations. <i>American Journal of Clinical Pathology</i> , 2012, 138, 579-589.	0.4	13
97	Emerging Strategies for Targeting Cell Adhesion in Multiple Myeloma. <i>Advances in Pharmacology</i> , 2012, 65, 143-189.	1.2	11
98	Genomic stratification of multiple myeloma treated with novel agents. <i>Leukemia and Lymphoma</i> , 2012, 53, 202-207.	0.6	13
99	Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. <i>Blood Cancer Journal</i> , 2012, 2, e53-e53.	2.8	66
100	Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1209-1222.	1.5	9
101	Antibodies. , 2012, , 70-78.		3
103	Targeted Therapy of Multiple Myeloma: The Changing Paradigm at the Beginning of the New Millennium. <i>Current Cancer Drug Targets</i> , 2012, 12, 743-756.	0.8	10
104	Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma. <i>Current Cancer Drug Targets</i> , 2012, 12, 797-813.	0.8	8
105	Advantageous use of lenalidomide in multiple myeloma. <i>Current Opinion in Oncology</i> , 2012, 24, S13-S20.	1.1	2
106	Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. <i>Haematologica</i> , 2012, 97, 1272-1277.	1.7	254
107	Myeloma:diagnosis complications and supportive care. <i>Hematology</i> , 2012, 17, s109-s111.	0.7	2
108	The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. <i>Blood</i> , 2012, 119, 7-15.	0.6	315
109	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. <i>Blood</i> , 2012, 119, 687-691.	0.6	274
110	Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. <i>Haematologica</i> , 2012, 97, 622-630.	1.7	44
111	Relapsed/Refractory Multiple Myeloma: Defining Refractory Disease and Identifying Strategies to Overcome Resistance. <i>Seminars in Hematology</i> , 2012, 49, S3-S15.	1.8	10
112	Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials. <i>American Journal of Pathology</i> , 2012, 181, 1870-1878.	1.9	22
113	Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. <i>Blood</i> , 2012, 119, 2100-2105.	0.6	218

#	ARTICLE	IF	CITATIONS
114	Karyotypic variability of human multiple myeloma cell lines. <i>Cell and Tissue Biology</i> , 2012, 6, 442-457.	0.2	2
115	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood</i> , 2012, 120, 1589-1596.	0.6	429
116	Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 2946-2955.	0.8	735
117	Emerging biological insights and novel treatment strategies in multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 407-438.	1.0	13
118	Risk stratification in Waldenström macroglobulinemia. <i>Expert Review of Hematology</i> , 2012, 5, 187-199.	1.0	16
119	Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. <i>Blood</i> , 2012, 119, 940-948.	0.6	327
120	Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. <i>Nature Genetics</i> , 2012, 44, 58-61.	9.4	137
121	Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype. <i>Leukemia</i> , 2012, 26, 1761-1770.	3.3	20
122	Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. <i>Human Pathology</i> , 2012, 43, 467-480.	1.1	20
123	Understanding the molecular biology of myeloma and its therapeutic implications. <i>Expert Review of Hematology</i> , 2012, 5, 603-617.	1.0	14
124	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
125	A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. <i>Leukemia</i> , 2012, 26, 349-355.	3.3	298
126	Can we change the disease biology of multiple myeloma?. <i>Leukemia Research</i> , 2012, 36, S3-S12.	0.4	50
127	First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. <i>The Cochrane Library</i> , 2012, 10, CD004626.	1.5	24
128	Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients. <i>Leukemia</i> , 2012, 26, 1862-1869.	3.3	73
129	Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma. <i>Cancer Genetics</i> , 2012, 205, 474-478.	0.2	16
130	Clonal Plasma Cell Pathophysiology and Clinical Features of Disease Are Linked to Clonal Plasma Cell Expression of Cyclin D1 in Systemic Light-Chain Amyloidosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 49-58.	0.2	28
131	TRAF6 Activation in Multiple Myeloma: A Potential Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 155-163.	0.2	55



#	ARTICLE	IF	CITATIONS
132	Risk Stratification of Plasma Cell Neoplasm: Insights From Plasma Cell-Specific Cytoplasmic Immunoglobulin Fluorescence in Situ Hybridization (clg FISH) vs. Conventional FISH. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 366-374.	0.2	9
133	Risk factors for unsuccessful peripheral blood stem cell harvesting using granulocyte-colony stimulating factor mobilization in patients with multiple myeloma. <i>Transfusion and Apheresis Science</i> , 2012, 47, 331-335.	0.5	12
134	Integrin-linked kinase is dispensable for multiple myeloma cell survival. <i>Leukemia Research</i> , 2012, 36, 1165-1171.	0.4	10
135	Fluorescence in situ hybridization analysis of chromosome aberrations in 60 Chinese patients with multiple myeloma. <i>Medical Oncology</i> , 2012, 29, 2200-2206.	1.2	10
136	<i>Myeloma and Leukemia</i> , 2012, , 509-529.		1
137	<i>The Centrosome</i> , 2012, , .		9
138	Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. <i>Future Oncology</i> , 2012, 8, 1223-1238.	1.1	11
139	1q21 amplification with additional genetic abnormalities but not isolated 1q21 gain is a negative prognostic factor in newly diagnosed patients with multiple myeloma treated with thalidomide-based regimens. <i>Leukemia and Lymphoma</i> , 2012, 53, 2500-2503.	0.6	10
140	<i>Molecular Aspects of Hematologic Malignancies. Principles and Practice</i> , 2012, , .	0.3	3
141	The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. <i>Blood Cancer Journal</i> , 2012, 2, e89-e89.	2.8	86
142	Minimal Residual Disease in Myeloma: Are We There Yet?. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1790-1799.	2.0	25
143	Molecular pathogenesis of multiple myeloma and its premalignant precursor. <i>Journal of Clinical Investigation</i> , 2012, 122, 3456-3463.	3.9	283
144	Evaluation of chromosomal abnormalities by clg-FISH and association with proliferative and apoptotic indexes in multiple myeloma. <i>Brazilian Journal of Medical and Biological Research</i> , 2012, 45, 1074-1079.	0.7	4
145	High detection rate of clinically relevant genomic abnormalities in plasma cells enriched from patients with multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 997-1006.	1.5	19
146	In multiple myeloma, bone marrow lymphocytes harboring the same chromosomal abnormalities as autologous plasma cells predict poor survival. <i>American Journal of Hematology</i> , 2012, 87, 579-587.	2.0	8
147	DNA methylation of microRNA genes in multiple myeloma. <i>Carcinogenesis</i> , 2012, 33, 1629-1638.	1.3	62
148	Utility of a column-free cell sorting system for separation of plasma cells in multiple myeloma FISH testing in clinical laboratories. <i>International Journal of Hematology</i> , 2012, 95, 274-281.	0.7	8
149	Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. <i>International Journal of Hematology</i> , 2012, 95, 516-526.	0.7	15

#	ARTICLE	IF	CITATIONS
150	Primary plasma cell leukemia in the era of new drugs: Has something changed?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 141-149.	2.0	18
151	The novel, orally bioavailable HSP90 inhibitor NVPâ€HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases. <i>European Journal of Haematology</i> , 2012, 88, 406-415.	1.1	22
152	Analysis of chromosome 12p deletion in plasma cell dyscrasias. <i>Leukemia Research</i> , 2012, 36, 32-36.	0.4	5
153	Identification of genetic parameters associated with disease progression in plasma cell myeloma. <i>Leukemia Research</i> , 2012, 36, 23-24.	0.4	0
154	New complex chromosome abnormalities in multiple myeloma associated with a poor prognosis: A case report. <i>Leukemia Research</i> , 2012, 36, e140-e142.	0.4	1
155	Overexpression of G proteinâ€coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2012, 42, 953-960.	1.7	79
156	Multiple myeloma: 2012 update on diagnosis, riskâ€stratification, and management. <i>American Journal of Hematology</i> , 2012, 87, 78-88.	2.0	120
157	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. <i>Hematological Oncology</i> , 2013, 31, 41-48.	0.8	39
158	Dissecting Karyotypic Patterns in Non-Hyperdiploid Multiple Myeloma: An Overview on the Karyotypic Evolution. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 552-558.	0.2	5
159	Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy. <i>International Journal of Hematology</i> , 2013, 97, 634-639.	0.7	1
161	Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. <i>Nature Genetics</i> , 2013, 45, 1221-1225.	9.4	143
162	Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations. <i>Annals of Hematology</i> , 2013, 92, 1129-1131.	0.8	11
164	5qâ€ syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide. <i>Leukemia Research</i> , 2013, 37, 1248-1250.	0.4	8
165	Myeloma: Classification and Risk Assessment. <i>Seminars in Oncology</i> , 2013, 40, 554-566.	0.8	24
166	Management of multiple myeloma in Asia: resource-stratified guidelines. <i>Lancet Oncology, The</i> , 2013, 14, e571-e581.	5.1	37
167	t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. <i>Leukemia Research</i> , 2013, 37, 1251-1257.	0.4	59
169	Multiple myeloma â€“ current status and future directions. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 793-804.	0.5	0
170	Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. <i>Blood</i> , 2013, 122, 219-226.	0.6	147

#	ARTICLE	IF	CITATIONS
171	Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. <i>Blood</i> , 2013, 121, 318-328.	0.6	112
172	Prognosis and Staging of Multiple Myeloma. , 2013, , 615-636.		2
173	Diagnosis and Treatment of Multiple Myeloma. , 2013, , 637-663.		2
174	Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. <i>Blood</i> , 2013, 121, 884-892.	0.6	153
175	Global real-time quantitative reverse transcription-polymerase chain reaction detecting proto-oncogenes associated with 14q32 chromosomal translocation as a valuable marker for predicting survival in multiple myeloma. <i>Leukemia Research</i> , 2013, 37, 1648-1655.	0.4	11
176	Hematological diseases: Prototypical conditions requiring the diagnostic and prognostic use of molecular data. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 382-392.	1.0	6
177	Impacto del tipo de hospital en la supervivencia de pacientes con mieloma múltiple: estudio MICORE. <i>Revista Clinica Espanola</i> , 2013, 213, 330-335.	0.2	2
178	The impact of the type of hospital on survival of multiple myeloma patients: The MICORE study. <i>Revista Clinica Espanola</i> , 2013, 213, 330-335.	0.3	0
179	Gain(1)(q21) is an Unfavorable Genetic Prognostic Factor for Patients With Relapsed Multiple Myeloma Treated With Thalidomide but Not for Those Treated With Bortezomib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 123-130.	0.2	20
180	Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. <i>Mayo Clinic Proceedings</i> , 2013, 88, 360-376.	1.4	440
181	The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. <i>Leukemia Research</i> , 2013, 37, 1070-1076.	0.4	15
182	Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2013, 90, 134-141.	1.1	32
183	Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1658-1664.	0.6	63
184	Multiple myeloma: 2013 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2013, 88, 225-235.	2.0	105
185	Molecular heterogeneity and centrosome-associated genes in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1982-1988.	0.6	6
186	History of Multiple Myeloma. , 2013, , 521-533.		0
187	Cytogenetic Abnormalities in MGUS and Myeloma. , 2013, , 589-599.		0
188	Molecular Genetics of Myeloma. , 2013, , 601-613.		0

#	ARTICLE	IF	CITATIONS
189	An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1. <i>British Journal of Cancer</i> , 2013, 108, 1870-1878.	2.9	12
190	Aberrant microRNA expression in multiple myeloma. <i>European Journal of Haematology</i> , 2013, 91, 95-105.	1.1	40
191	Molecular pathogenesis of multiple myeloma: basic and clinical updates. <i>International Journal of Hematology</i> , 2013, 97, 313-323.	0.7	118
192	Perspectives in the treatment of multiple myeloma. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, S1-S22.	1.4	18
193	Minor clone provides a reservoir for relapse in multiple myeloma. <i>Leukemia</i> , 2013, 27, 473-481.	3.3	112
194	Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization are complementary techniques to detect cytogenetic abnormalities in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 785-793.	1.5	19
195	The Cytogenetics of Hematologic Neoplasms. , 2013, , 309-370.		1
196	Cytogenetics of extramedullary manifestations in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 161, 87-94.	1.2	81
197	Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype. <i>Leukemia</i> , 2013, 27, 925-931.	3.3	31
198	Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia. <i>Haematologica</i> , 2013, 98, 649-654.	1.7	119
199	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i> , 2013, 98, 1753-1761.	1.7	300
200	Current approaches to the initial treatment of symptomatic multiple myeloma. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 61-70.	0.7	11
201	Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. <i>Leukemia</i> , 2013, 27, 1738-1744.	3.3	194
202	Incidence and prognostic value of recurrent chromosomal abnormalities in elderly patients with multiple myeloma. <i>Future Oncology</i> , 2013, 9, 1805-1808.	1.1	2
203	The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2013, 19, 4634-4637.	3.2	12
204	Apoptotic Machinery Diversity in Multiple Myeloma Molecular Subtypes. <i>Frontiers in Immunology</i> , 2013, 4, 467.	2.2	24
205	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 478-487.	0.9	69
206	Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma. <i>British Journal of Haematology</i> , 2013, 163, 223-234.	1.2	7

#	ARTICLE	IF	CITATIONS
207	Prognostic value of high serum lactate dehydrogenase in plasma cell dyscrasias: a re-evaluation in the context of cytogenetic aberration data. <i>Leukemia and Lymphoma</i> , 2013, 54, 2556-2559.	0.6	3
208	Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma. <i>European Journal of Haematology</i> , 2013, 91, 193-195.	1.1	2
209	A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. <i>Leukemia</i> , 2013, 27, 1754-1757.	3.3	36
210	Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. <i>Leukemia</i> , 2013, 27, 2351-2356.	3.3	72
211	New mitogens in cultures for multiple myeloma cytogenetic analysis. <i>Leukemia and Lymphoma</i> , 2013, 54, 2548-2550.	0.6	1
212	Plasma Cell Enrichment Enhances Detection of High-Risk Cytogenomic Abnormalities by Fluorescence In Situ Hybridization and Improves Risk Stratification of Patients With Plasma Cell Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 625-631.	1.2	22
213	The genetic and epigenetic mechanisms underlying the behavior of myeloma. , 0, , 48-63.		0
214	Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. <i>Haematologica</i> , 2013, 98, 279-287.	1.7	36
217	Strategies for the Treatment of Multiple Myeloma in 2013: Moving Toward the Cure. , 0, , .		0
218	Cytogenetics and Chromosomal Abnormalities in Multiple Myeloma-A Review. <i>Cloning &amp; Transgenesis</i> , 2013, 02, .	0.1	1
219	Impact of Genetic Abnormalities on the Prognoses and Clinical Parameters of Patients with Multiple Myeloma. <i>Annals of Laboratory Medicine</i> , 2013, 33, 248-254.	1.2	21
220	Diagnosis and therapy of multiple myeloma. <i>Korean Journal of Internal Medicine</i> , 2013, 28, 263.	0.7	17
221	Inhibition of DEPDC1A, a Bad Prognostic Marker in Multiple Myeloma, Delays Growth and Induces Mature Plasma Cell Markers in Malignant Plasma Cells. <i>PLoS ONE</i> , 2013, 8, e62752.	1.1	24
222	Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e83252.	1.1	13
223	A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma. <i>PLoS ONE</i> , 2013, 8, e66361.	1.1	41
224	Randomized Clinical Trial of Zoledronic Acid in Multiple Myeloma Patients Undergoing High-Dose Chemotherapy and Stem-Cell Transplantation. <i>Current Oncology</i> , 2013, 20, 13-20.	0.9	17
225	Multiple Myeloma: An Update. <i>Oman Medical Journal</i> , 2013, 28, 3-11.	0.3	33
226	New Tools for Diagnosis and Monitoring of Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , e313-e318.	1.8	8

#	ARTICLE	IF	CITATIONS
227	Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma. PLoS ONE, 2014, 9, e110973.	1.1	29
228	The Role of miRNAs in Plasma Cell Dyscrasias. MicroRNA (Sharjah, United Arab Emirates), 2014, 2, 165-173.	0.6	3
229	Chromosome 1 Abnormalities Predict Shortened Progression Free and Overall Survival in Patients with High Risk Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation, a Retrospective Analysis. Journal of Blood & Lymph, 2014, 05, .	0.0	0
230	Multiple myeloma: optimal management and long-term disease control. Blood and Lymphatic Cancer: Targets and Therapy, 2014, , 121.	1.2	0
231	GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target. Blood Cancer Journal, 2014, 4, e175-e175.	2.8	46
232	The role of epigenetics in the biology of multiple myeloma. Blood Cancer Journal, 2014, 4, e207-e207.	2.8	106
233	Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma. Leukemia, 2014, 28, 894-903.	3.3	19
234	Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia, 2014, 28, 1573-1585.	3.3	108
235	Implications of Heterogeneity in Multiple Myeloma. BioMed Research International, 2014, 2014, 1-12.	0.9	43
236	Multiple myeloma: a model for scientific and clinical progress. Hematology American Society of Hematology Education Program, 2014, 2014, 1-7.	0.9	17
237	Genomic profiling of plasma cell disorders in a clinical setting: integration of microarray and FISH, after CD138 selection of bone marrow. Journal of Clinical Pathology, 2014, 67, 66-69.	1.0	12
238	Genome-Wide Screening of Cytogenetic Abnormalities in Multiple Myeloma Patients Using Array-CGH Technique: A Czech Multicenter Experience. BioMed Research International, 2014, 2014, 1-9.	0.9	23
239	MicroRNA: Important Player in the Pathobiology of Multiple Myeloma. BioMed Research International, 2014, 2014, 1-12.	0.9	43
240	IMWG consensus on risk stratification in multiple myeloma. Leukemia, 2014, 28, 269-277.	3.3	500
241	The potential of miRNAs as biomarkers for multiple myeloma. Expert Review of Molecular Diagnostics, 2014, 14, 947-959.	1.5	23
242	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	1.7	185
243	Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma. British Journal of Cancer, 2014, 111, 1293-1304.	2.9	19
244	Cytogenetic classification in <sc>K</sc>orean multiple myeloma patients: prognostic significance of hyperdiploidy with 47-50 chromosomes and the number of structural abnormalities. European Journal of Haematology, 2014, 92, 313-320.	1.1	11

#	ARTICLE	IF	CITATIONS
245	First line and salvage therapy with total therapy 3-based treatment for multiple myeloma—An extended single center experience. <i>Leukemia Research</i> , 2014, 38, 1401-1406.	0.4	10
246	Can genome array screening replace FISH as a front-line test in multiple myeloma?. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 676-692.	1.5	11
247	Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. <i>Leukemia</i> , 2014, 28, 675-679.	3.3	91
248	Biology and Treatment of Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S65-S70.	0.2	15
249	Asymptomatic Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S78-S86.	0.2	6
251	Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 299.	0.4	6
252	Pathogenesis of Multiple Myeloma. , 2014, , 35-46.		0
255	The RAG Model: A New Paradigm for Genetic Risk Stratification in Multiple Myeloma. <i>Bone Marrow Research</i> , 2014, 2014, 1-9.	1.7	5
256	The Genetic Architecture of Multiple Myeloma. <i>Advances in Hematology</i> , 2014, 2014, 1-16.	0.6	79
257	Current strategies for treatment of relapsed/refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 97-111.	1.0	65
258	The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy. <i>International Journal of Hematology</i> , 2014, 99, 288-295.	0.7	20
259	New Approaches to Management of Multiple Myeloma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 157-170.	1.3	19
260	The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma. <i>Molecular Cancer</i> , 2014, 13, 25.	7.9	10
261	Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens. <i>American Journal of Hematology</i> , 2014, 89, 616-620.	2.0	34
262	Modified clg-FISH protocol for multiple myeloma in routine cytogenetic laboratory practice. <i>Cancer Genetics</i> , 2014, 207, 31-34.	0.2	10
263	Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy. <i>Cancer Cell</i> , 2014, 25, 91-101.	7.7	847
264	Molecular Testing in Cancer. , 2014, , .		2
265	Staging and prognostication of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 21-31.	1.0	33



#	ARTICLE	IF	CITATIONS
266	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014, 5, 2997.	5.8	741
267	International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 587-600.	0.8	330
269	Biologic Frontiers in Multiple Myeloma: From Biomarker Identification to Clinical Practice. <i>Clinical Cancer Research</i> , 2014, 20, 804-813.	3.2	29
270	High-Risk Multiple Myeloma: Different Definitions, Different Outcomes?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 24-30.	0.2	8
271	Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. <i>Haematologica</i> , 2014, 99, 353-359.	1.7	111
272	Myeloma Genetics and Genomics: Practice Implications and Future Directions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 436-440.	0.2	15
273	Multiple myeloma: 2014 Update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2014, 89, 998-1009.	2.0	148
274	Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations. <i>Leukemia</i> , 2014, 28, 1747-1750.	3.3	13
275	Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 356-369.	0.2	7
277	Molecular insights into dimerization inhibition of c-Maf transcription factor. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2014, 1844, 2108-2115.	1.1	13
278	The impact of intra-clonal heterogeneity on the treatment of multiple myeloma. <i>British Journal of Haematology</i> , 2014, 165, 441-454.	1.2	91
279	Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders. <i>Blood Cells, Molecules, and Diseases</i> , 2014, 53, 110-117.	0.6	9
280	SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma. <i>Neoplasia</i> , 2014, 16, 572-585.	2.3	36
281	Diagnosis and Risk Stratification in Multiple Myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 791-813.	0.9	19
282	Controversies in Multiple Myeloma: to Transplant or Not?. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 360-367.	1.2	4
283	Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. <i>Annals of Hematology</i> , 2014, 93, 1353-1361.	0.8	18
284	Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. <i>Blood</i> , 2014, 123, 697-705.	0.6	184
285	Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 9-17.	1.4	84



#	ARTICLE	IF	CITATIONS
286	Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian context. <i>Molecular Cytogenetics</i> , 2014, 7, 24.	0.4	5
287	Relationship between initial clinical presentation and the molecular cytogenetic classification of myeloma. <i>Leukemia</i> , 2014, 28, 398-403.	3.3	60
288	High-Risk Myeloma: When To Transplant Or Not. <i>Seminars in Oncology</i> , 2014, 41, e1-e9.	0.8	0
289	Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 131-139.e1.	0.2	54
290	Multiple Myeloma and Evolution of Novel Biomarkers and Therapies. , 2014, , 895-934.		0
291	Multiple Myeloma and Evolution of Novel Biomarkers and Therapies. , 2014, , 871-908.		0
292	Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). <i>Blood</i> , 2014, 123, 78-85.	0.6	173
293	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , 2014, 124, 3110-3117.	0.6	54
294	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. <i>Haematologica</i> , 2014, 99, 1611-1617.	1.7	29
295	Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. <i>Haematologica</i> , 2014, 99, 360-364.	1.7	133
296	Multiple Myeloma Treatment and Management in the Elderly. <i>The Consultant Pharmacist</i> , 2014, 29, 434-451.	0.4	9
298	Cohort analysis of FISH testing of CD138 <sup>+</sup> cells in relapsed multiple myeloma: implications for prognosis and choice of therapy. <i>British Journal of Haematology</i> , 2015, 171, 881-883.	1.2	8
299	Advances in the pathogenesis and diagnosis of multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 108-114.	0.7	41
300	How I treat high-risk myeloma. <i>Blood</i> , 2015, 126, 1536-1543.	0.6	77
301	Blind men and an elephant. <i>Blood</i> , 2015, 125, 745-747.	0.6	3
302	Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. <i>Rare Cancers and Therapy</i> , 2015, 3, 47-68.	0.2	14
303	High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2015, 8, 77.	6.9	27
304	Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort. <i>Apmis</i> , 2015, 123, 652-658.	0.9	20

#	ARTICLE	IF	CITATIONS
305	Atypical IgM multiple myeloma with deletion of <i>MAF</i> . International Journal of Laboratory Hematology, 2015, 37, 686-689.	0.7	0
306	Multiple Myeloma: Is It Time for Biomarker-Driven Therapy?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e493-e503.	1.8	11
307	Induction Therapy with Bortezomib, Thalidomide and Dexamethasone (VTD) in Caucasian Patients with Multiple Myeloma: A Single Center Experience. Journal of Blood Disorders & Transfusion, 2015, 06, .	0.1	0
308	Adverse Prognostic Impact of Bone Marrow Microvessel Density in Multiple Myeloma. Annals of Laboratory Medicine, 2015, 35, 563-569.	1.2	15
309	Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. BioMed Research International, 2015, 2015, 1-8.	0.9	13
310	Extramedullary Manifestation in Multiple Myeloma Bears High Incidence of Poor Cytogenetic Aberration and Novel Agents Resistance. BioMed Research International, 2015, 2015, 1-7.	0.9	28
311	MicroC <sup>3</sup> : an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integrative Biology (United Kingdom), 2015, 7, 643-654.	0.6	42
312	Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. Molecular Cancer, 2015, 14, 175.	7.9	40
313	Diagnosis and staging. , 2015, , 15-28.		0
314	Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Annals of Hematology, 2015, 94, 257-264.	0.8	52
315	The molecular spectrum and clinical impact of <i>DIS3</i> mutations in multiple myeloma. British Journal of Haematology, 2015, 169, 57-70.	1.2	61
316	Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study. Blood Cancer Journal, 2015, 5, e271-e271.	2.8	27
317	An update on molecular biology and drug resistance mechanisms of multiple myeloma. Critical Reviews in Oncology/Hematology, 2015, 96, 413-424.	2.0	11
318	Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. Journal of Clinical Oncology, 2015, 33, 2863-2869.	0.8	1,525
320	Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients. Cancer, 2015, 121, 853-862.	2.0	1
321	Management of Elderly Patients with Plasma Cell Myeloma. Drugs and Aging, 2015, 32, 427-442.	1.3	1
322	Genomic heterogeneity in multiple myeloma. Current Opinion in Genetics and Development, 2015, 30, 56-65.	1.5	31
323	Autophagic Markers BECLIN 1 and LC3 Are Associated with Prognosis of Multiple Myeloma. Acta Haematologica, 2015, 134, 17-24.	0.7	28

#	ARTICLE	IF	CITATIONS
324	The t(11;14)(q13;q32) Translocation as a Poor Prognostic Parameter for Autologous Stem Cell Transplantation in Myeloma Patients With Extramedullary Plasmacytoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 227-235.	0.2	19
325	Cytogenetic and clinical marks for defining high-risk myeloma in the context of bortezomib treatment. <i>Experimental Hematology</i> , 2015, 43, 168-176.e2.	0.2	13
326	Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 857-872.	1.4	18
327	Removing batch effects from purified plasma cell gene expression microarrays with modified ComBat. <i>BMC Bioinformatics</i> , 2015, 16, 63.	1.2	73
328	New aspects on the pathogenesis of renal disorders related to monoclonal gammopathies. <i>Nephrologie Et Therapeutique</i> , 2015, 11, 135-143.	0.2	19
329	The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence <i>In Situ</i> Hybridization in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 2148-2156.	3.2	76
330	A critical review of the epidemiology of Agent Orange or 2,3,7,8-tetrachlorodibenzo-p-dioxin and lymphoid malignancies. <i>Annals of Epidemiology</i> , 2015, 25, 275-292.e30.	0.9	15
331	Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma. <i>British Medical Bulletin</i> , 2015, 113, 15-30.	2.7	16
332	DNA methylation of tumor suppressor protein-coding and non-coding genes in multiple myeloma. <i>Epigenomics</i> , 2015, 7, 985-1001.	1.0	29
333	Interpretation of cytogenetic results in multiple myeloma for clinical practice. <i>Blood Cancer Journal</i> , 2015, 5, e365-e365.	2.8	163
334	Cytogenetic Alterations in Multiple Myeloma: Prognostic Significance and the Choice of Frontline Therapy. <i>Cancer Investigation</i> , 2015, 33, 496-504.	0.6	11
335	Appraising myc involvement in high risk myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 551-552.	0.6	4
336	Defining and treating high-risk multiple myeloma. <i>Leukemia</i> , 2015, 29, 2119-2125.	3.3	55
337	Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. <i>Nature Communications</i> , 2015, 6, 8428.	5.8	53
338	SnapShot: Multiple Myeloma. <i>Cancer Cell</i> , 2015, 28, 678-678.e1.	7.7	31
339	Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. <i>International Journal of Cancer</i> , 2015, 136, 1835-1844.	2.3	60
340	16. Tumorgenetik. , 2016, , 291-300.		0
341	13. Molecular pathogenesis of multiplemyeloma. , 2016, , 245-256.		0

#	ARTICLE	IF	CITATIONS
342	The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population. <i>OncoTargets and Therapy</i> , 2016, 9, 295.	1.0	11
343	Non-secretory multiple myeloma: from biology to clinical management. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 7583-7590.	1.0	39
344	Abnormalities in Chromosomes 1q and 13 Independently Correlate With Factors of Poor Prognosis in Multiple Myeloma. <i>Annals of Laboratory Medicine</i> , 2016, 36, 573-582.	1.2	6
345	Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma. <i>Theranostics</i> , 2016, 6, 2209-2224.	4.6	71
346	Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2003.	1.8	59
347	The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD). <i>Oncotarget</i> , 2016, 7, 9666-9679.	0.8	33
348	Cytogenetics in multiple myeloma patients progressing into extramedullary disease. <i>European Journal of Haematology</i> , 2016, 97, 93-100.	1.1	37
349	Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 710-718.	1.5	28
352	Clinical significance of granule-containing myeloma cells in patients with newly diagnosed multiple myeloma. <i>Cancer Medicine</i> , 2016, 5, 3051-3058.	1.3	3
354	MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. <i>Blood</i> , 2016, 128, 2919-2930.	0.6	57
355	Centrosome associated genes pattern for risk sub-stratification in multiple myeloma. <i>Journal of Translational Medicine</i> , 2016, 14, 150.	1.8	18
356	Bortezomib-based induction improves progression-free survival of myeloma patients harboring 17p deletion and/or t(4;14) and overcomes their adverse prognosis. <i>Annals of Hematology</i> , 2016, 95, 1315-1321.	0.8	13
357	Role of Flow Cytometry in the Diagnosis and Prognosis of Plasma Cell Myeloma. <i>Surgical Pathology Clinics</i> , 2016, 9, 101-116.	0.7	7
358	Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. <i>Blood</i> , 2016, 127, 2955-2962.	0.6	686
359	A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. <i>Blood Cancer Journal</i> , 2016, 6, e467-e467.	2.8	59
360	Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach. <i>Journal of Clinical Oncology</i> , 2016, 34, 3600-3604.	0.8	18
361	Epigenetics in Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 35-49.	0.2	7
362	Genomic Aberrations in Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 23-34.	0.2	21

#	ARTICLE	IF	CITATIONS
363	Treatment of Newly Diagnosed Elderly Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 123-143.	0.2	9
365	How to Think About Risk in Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S135-S138.	0.2	1
366	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
367	Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 610-615.	0.2	12
368	Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. <i>American Journal of Hematology</i> , 2016, 91, E442-7.	2.0	16
369	Treatment of newly diagnosed myeloma: Bortezomib-based triplet. <i>Seminars in Oncology</i> , 2016, 43, 700-702.	0.8	9
370	Primary plasma cell leukemia 2.0: advances in biology and clinical management. <i>Expert Review of Hematology</i> , 2016, 9, 1063-1073.	1.0	15
371	Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 49.	3.5	4
372	HIF-1 $\alpha$ and rapamycin act as gerosuppressant in multiple myeloma cells upon genotoxic stress. <i>Cell Cycle</i> , 2016, 15, 2174-2182.	1.3	8
373	Are maintenance and continuous therapies indicated for every patient with multiple myeloma?. <i>Expert Review of Hematology</i> , 2016, 9, 743-751.	1.0	13
374	Frequent occurrence of large duplications at reciprocal genomic rearrangement breakpoints in multiple myeloma and other tumors. <i>Nucleic Acids Research</i> , 2016, 44, 8189-8198.	6.5	11
375	Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group. <i>Bone Marrow Transplantation</i> , 2016, 51, 933-937.	1.3	18
376	Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow. <i>Journal of Hematopathology</i> , 2016, 9, 9-18.	0.2	6
377	Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 113-120.	0.7	12
378	Experimental treatment of multiple myeloma in the era of precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 37-51.	0.4	5
379	Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?. <i>Immunotherapy</i> , 2016, 8, 367-384.	1.0	6
380	Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. <i>Leukemia and Lymphoma</i> , 2016, 57, 2058-2064.	0.6	12
381	Single-cell analysis of targeted transcriptome predicts drug sensitivity of single cells within human myeloma tumors. <i>Leukemia</i> , 2016, 30, 1094-1102.	3.3	64

#	ARTICLE	IF	CITATIONS
382	Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 191-205.	1.0	4
383	A noninterventional observational registry of patients with multiple myeloma treated with lenalidomide in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 705-710.	0.8	3
384	Pomalidomide in heavily pretreated refractory multiple myeloma: a case report. <i>Future Oncology</i> , 2017, 13, 7-9.	1.1	3
385	Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma. <i>Future Oncology</i> , 2017, 13, 3-6.	1.1	6
386	RGS1 expression is associated with poor prognosis in multiple myeloma. <i>Journal of Clinical Pathology</i> , 2017, 70, 202-207.	1.0	27
387	Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker. <i>Blood Cancer Journal</i> , 2017, 7, e535-e535.	2.8	48
388	Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e528-e528.	2.8	39
390	Cutting edge genomics reveal new insights into tumour development, disease progression and therapeutic impacts in multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 196-208.	1.2	17
391	Cancer Cytogenetics. <i>Methods in Molecular Biology</i> , 2017, , .	0.4	4
392	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 230-269.	2.3	166
393	High-throughput sequencing for noninvasive disease detection in hematologic malignancies. <i>Blood</i> , 2017, 130, 440-452.	0.6	66
394	Therapy for Relapsed Multiple Myeloma. <i>Mayo Clinic Proceedings</i> , 2017, 92, 578-598.	1.4	115
395	Mechanisms of Resistance in Multiple Myeloma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 251-288.	0.9	20
396	Cytoplasmic Immunoglobulin Light Chain Revelation and Interphase Fluorescence In Situ Hybridization in Myeloma. <i>Methods in Molecular Biology</i> , 2017, 1541, 127-142.	0.4	1
397	Detection of complex genomic signatures associated with risk in plasma cell disorders. <i>Cancer Genetics</i> , 2017, 218-219, 1-9.	0.2	7
398	Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. <i>Blood</i> , 2017, 130, 2610-2618.	0.6	90
399	Multiple Myeloma Genomics: A Systematic Review. <i>Seminars in Oncology Nursing</i> , 2017, 33, 237-253.	0.7	19
400	High-risk Multiple Myeloma: Definition and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S80-S87.	0.2	34

#	ARTICLE	IF	CITATIONS
401	Diagnostik lymphatischer Neoplasien. <i>Laboratoriums Medizin</i> , 2017, 41, 285-297.	0.1	1
402	Expressed fusion gene landscape and its impact in multiple myeloma. <i>Nature Communications</i> , 2017, 8, 1893.	5.8	31
403	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2017, , .	3.3	9
404	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 621-630.	0.2	5
405	Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients. <i>BBA Clinical</i> , 2017, 8, 28-34.	4.1	19
406	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.2	28
407	Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma. <i>Experimental Hematology and Oncology</i> , 2017, 6, 16.	2.0	6
408	A gene expression signature distinguishes innate response and resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e581-e581.	2.8	37
409	Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion. <i>Modern Pathology</i> , 2017, 30, 1378-1386.	2.9	6
410	Genomic complexity of multiple myeloma and its clinical implications. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 100-113.	12.5	413
411	Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. <i>Leukemia</i> , 2017, 31, 637-644.	3.3	27
412	High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma. <i>Blood Cancer Journal</i> , 2017, 7, e612-e612.	2.8	132
413	Telomere protein complexes and their role in lymphoid malignancies. <i>Frontiers in Bioscience - Scholar</i> , 2017, 9, 17-30.	0.8	3
414	Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. <i>Frontiers in Immunology</i> , 2017, 8, 1444.	2.2	62
415	Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review. <i>International Journal of Genomics</i> , 2017, 2017, 1-6.	0.8	5
416	Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p). <i>Oncotarget</i> , 2017, 8, 62435-62444.	0.8	11
417	Chromothripsis in Treatment Resistance in Multiple Myeloma. <i>Genomics and Informatics</i> , 2017, 15, 87-97.	0.4	13
419	The multiple myelomas "current concepts in cytogenetic classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 409-421.	12.5	203



#	ARTICLE	IF	CITATIONS
420	Genetic alterations crossing the borders of distinct hematopoietic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 64-79.	2.0	12
421	Microfluidic enrichment of plasma cells improves treatment of multiple myeloma. <i>Molecular Oncology</i> , 2018, 12, 1004-1011.	2.1	9
422	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. <i>Annals of Hematology</i> , 2018, 97, 1453-1462.	0.8	26
423	Calorimetric markers for monitoring of multiple myeloma and Waldenström's macroglobulinemia patients. <i>European Biophysics Journal</i> , 2018, 47, 549-559.	1.2	9
424	Distinct predictive impact of <sc>FISH</sc> abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. <i>Cancer Medicine</i> , 2018, 7, 831-841.	1.3	12
425	Cytogenetic Profiling of Myelomas, Association With Complete Blood Count: Study of 180 Patients. <i>Laboratory Medicine</i> , 2018, 49, 68-74.	0.8	1
426	Evaluation of CD229 as a new alternative plasma cell gating marker in the flow cytometric immunophenotyping of monoclonal gammopathies. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 509-519.	0.7	14
428	Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents. <i>Leukemia</i> , 2018, 32, 1267-1276.	3.3	18
429	Is the revised International staging system for myeloma valid in a real world population?. <i>British Journal of Haematology</i> , 2018, 180, 451-454.	1.2	12
430	Expression of genes MAGE-A3 MAGE-C1, NY-ESO-1 and SSX1 in patients with multiple myeloma at the General Hospital of Mexico. <i>Revista Médica Del Hospital General De México</i> , 2018, 81, 86-92.	0.0	0
431	Minimal residual disease in multiple myeloma: Benefits of flow cytometry. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 12-20.	0.7	8
433	Epigenetics in multiple myeloma: From mechanisms to therapy. <i>Seminars in Cancer Biology</i> , 2018, 51, 101-115.	4.3	59
434	Chemotherapy-Based Stem Cell Mobilization Does Not Result in Significant Paraprotein Reduction in Myeloma Patients in the Era of Novel Induction Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 276-281.	2.0	16
435	MicroRNA-324p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling. <i>International Journal of Cancer</i> , 2018, 142, 109-120.	2.3	61
436	14-3-3 binds the proteasome, limits proteolytic function and enhances sensitivity to proteasome inhibitors. <i>Leukemia</i> , 2018, 32, 744-751.	3.3	12
437	Neurologic Complications of Plasma Cell Dyscrasias. , 2018, , 583-595.		1
438	Prevalence and clinicopathologic characteristics of multiple myeloma with cutaneous involvement: A case series from Korea. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 471-478.e4.	0.6	22
439	&lt;b>Serum free light chain-only multiple myeloma associated with multiple bone involvement and the t(11;14)(q13;q32)&lt;/b>&lt;b>&lt;i>CCND1&lt;/i&lt;/b>-immunoglobulin heavy chain fusion gene: A report of three case&lt;b>s&lt;/b>. <i>Tenri Medical Bulletin</i> , 2018, 21, 56-69.	0.1	0



#	ARTICLE	IF	CITATIONS
440	Hyperdiploidy is a Positive Prognostic Factor for Progression-Free Survival in Multiple Myeloma with High and Intermediate Risk Cytogenetics. <i>Health Science Journal</i> , 2018, 12, .	0.8	1
441	A novel derivative (GTN024) from a natural product, komaroviquinone, induced the apoptosis of high-risk myeloma cells via reactive oxygen production and ER stress. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 787-793.	1.0	4
442	Genetic Aspects of Hematopoietic Malignancies. , 2018, , 201-234.		1
443	Prevention of Bortezomib-Related Peripheral Neuropathy With Docosahexaenoic Acid and $\alpha$ -Lipoic Acid in Patients With Multiple Myeloma: Preliminary Data. <i>Integrative Cancer Therapies</i> , 2018, 17, 1115-1124.	0.8	23
444	The challenges of checkpoint inhibition in the treatment of multiple myeloma. <i>Cellular Immunology</i> , 2018, 334, 87-98.	1.4	15
445	Prognostic factors for multiple myeloma in the era of novel therapies. <i>Expert Review of Hematology</i> , 2018, 11, 863-879.	1.0	28
446	Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience. <i>Annals of Laboratory Medicine</i> , 2018, 38, 196-203.	1.2	10
447	Targeting EZH2 in Multiple Myeloma—Multifaceted Anti-Tumor Activity. <i>Epigenomes</i> , 2018, 2, 16.	0.8	18
448	Prognostic impact of hyperdiploidy in multiple myeloma patients with high-risk cytogenetics: a pilot study in China. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2263-2273.	1.2	10
449	Spinal metastases in multiple myeloma: A high-risk subgroup for ISS III patients. <i>Surgical Oncology</i> , 2018, 27, 321-326.	0.8	5
450	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018, 32, 2604-2616.	3.3	137
451	How I treat the young patient with multiple myeloma. <i>Blood</i> , 2018, 132, 1114-1124.	0.6	38
452	LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity. <i>Experimental Cell Research</i> , 2018, 370, 254-263.	1.2	15
453	Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. <i>Oncolmmunology</i> , 2018, 7, e1486948.	2.1	41
454	Clinicopathological Characteristics of Hyperdiploidy with High-Risk Cytogenetics in Multiple Myeloma. <i>Annals of Laboratory Medicine</i> , 2018, 38, 160-164.	1.2	1
455	The NF- $\kappa$ B Activating Pathways in Multiple Myeloma. <i>Biomedicines</i> , 2018, 6, 59.	1.4	57
456	The Role of Chromosomal Instability in Cancer and Therapeutic Responses. <i>Cancers</i> , 2018, 10, 4.	1.7	128
457	CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma. <i>Molecular Therapy</i> , 2018, 26, 1906-1920.	3.7	38

#	ARTICLE	IF	CITATIONS
458	Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 40.	1.8	1
459	Potential Clinical Application of Genomics in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1721.	1.8	5
460	The histopathology of myeloma in the bone marrow. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2018, 58, 61-67.	0.3	13
461	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2087.	1.8	14
462	Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse. <i>Molecular Cytogenetics</i> , 2018, 11, 7.	0.4	11
463	High-Throughput Copy Number Profiling by Digital Multiplex Ligation-Dependent Probe Amplification in Multiple Myeloma. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 777-788.	1.2	13
464	Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2019, 187, 447-458.	1.2	7
465	A Rare Presentation of Biclonal Gammopathy in Multiple Myeloma with Simultaneous Extramedullary Involvement: A Case Report. <i>Case Reports in Oncology</i> , 2019, 12, 537-542.	0.3	4
466	High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2019, 8, 997.	1.0	45
467	The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis. <i>FASEB BioAdvances</i> , 2019, 1, 404-414.	1.3	17
468	Wwox Deletion in Mouse B Cells Leads to Genomic Instability, Neoplastic Transformation, and Monoclonal Gammopathies. <i>Frontiers in Oncology</i> , 2019, 9, 517.	1.3	4
469	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2134-2142.	2.0	52
470	Immunohistochemistry for identification of <i>CCND1</i> , <i>NSD2</i> , and <i>MAF</i> gene rearrangements in plasma cell myeloma. <i>Cancer Science</i> , 2019, 110, 2600-2606.	1.7	6
471	Characteristics of long-term survivors with multiple myeloma: A National Cancer Data Base analysis. <i>Cancer</i> , 2019, 125, 3574-3581.	2.0	7
472	Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 65.	6.9	7
473	Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1695.	1.0	7
474	Plasma cell myeloma positive for t(14;20) with relapse in the central nervous system. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2019, 59, 135-139.	0.3	2
475	Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. <i>Leukemia</i> , 2019, 33, 2710-2719.	3.3	28

#	ARTICLE	IF	CITATIONS
476	Chicken or Egg: Is Clonal Hematopoiesis Primarily Caused by Genetic or Epigenetic Aberrations?. <i>Frontiers in Genetics</i> , 2019, 10, 785.	1.1	3
477	Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma. <i>Molecular Omics</i> , 2019, 15, 7-20.	1.4	9
478	Laboratory assessment of multiple myeloma. <i>Advances in Clinical Chemistry</i> , 2019, 89, 1-58.	1.8	23
479	Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16). <i>Genes Chromosomes and Cancer</i> , 2019, 58, 516-520.	1.5	4
480	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, E117-E120.	2.0	13
481	Prognostic Value of 1q21 Gain in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e159-e164.	0.2	12
482	Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2019, 10, 1121.	2.2	103
483	Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2019, 2019, 1-10.	0.9	12
484	Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1657-1665.	0.8	111
485	Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 853-861.	2.0	33
487	Intelligent Microarray Data Analysis through Non-negative Matrix Factorization to Study Human Multiple Myeloma Cell Lines. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 5552.	1.3	9
488	Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2019, 3, 603-611.	2.5	10
489	TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC. <i>Blood Advances</i> , 2019, 3, 3613-3625.	2.5	19
490	The Effect of Docosahexaenoic Acid and Î±-Lipoic Acid as Prevention of Bortezomib-Related Neurotoxicity in Patients With Multiple Myeloma. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541988858.	0.8	7
491	Identification specific miRNA in t(4;14) multiple myeloma based on miRNA-mRNA expressing profile correlation analysis. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 2454-2468.	1.2	5
492	CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1 <sup>hi</sup> mantle cell lymphoma. <i>Blood</i> , 2019, 133, 940-951.	0.6	77
493	SLAMF receptors on normal and malignant B cells. <i>Clinical Immunology</i> , 2019, 204, 23-30.	1.4	10
494	3-BrBromopyruvate as a potent anticancer therapy in honor and memory of the late Professor Andr�� Goffeau. <i>Yeast</i> , 2019, 36, 211-221.	0.8	13

#	ARTICLE	IF	CITATIONS
495	Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2085-2087.	0.6	2
496	Genetic and transcriptional landscape of plasma cells in POEMS syndrome. <i>Leukemia</i> , 2019, 33, 1723-1735.	3.3	28
497	WWOX, the FRA16D gene: A target of and a contributor to genomic instability. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 324-338.	1.5	28
498	The impact of NF- $\kappa$ B signaling on pathogenesis and current treatment strategies in multiple myeloma. <i>Blood Reviews</i> , 2019, 34, 56-66.	2.8	87
499	IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification. <i>Haematologica</i> , 2020, 105, 1391-1404.	1.7	34
500	An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. <i>Biometrics</i> , 2020, 76, 304-315.	0.8	12
501	Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 284-291.	0.3	2
502	Risk Stratification in Multiple Myeloma in Indian Settings. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2020, 36, 464-472.	0.3	3
503	Multiple Myeloma and Related Disorders. , 2020, , 1884-1910.e7.		4
504	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 798-804.	2.0	28
505	Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. <i>Advances in Anatomic Pathology</i> , 2020, 27, 61-74.	2.4	25
506	Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China. <i>Frontiers of Medicine</i> , 2020, 14, 327-334.	1.5	4
507	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	1.2	8
508	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	3.2	32
509	A Wolf in Sheep's clothing: A case report series of oral manifestations of multiple myeloma. <i>Australian Dental Journal</i> , 2021, 66, 324-331.	0.6	6
510	Risk and Response-Adapted Treatment in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3497.	1.7	10
511	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	2.5	58
512	The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 108.	6.9	20

#	ARTICLE	IF	CITATIONS
513	Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23416.	0.9	9
514	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	2.8	59
515	Targeting NF- $\kappa$ B Signaling for Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2203.	1.7	24
516	The roles of TRAF3 mutation in the oncogenic progression and drug response of multiple myeloma. <i>Genome Instability &amp; Disease</i> , 2020, 1, 278-285.	0.5	0
518	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. <i>Journal of Hematology and Oncology</i> , 2020, 13, 115.	6.9	32
519	Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. <i>Blood Cancer Journal</i> , 2020, 10, 111.	2.8	13
520	IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 105, 326-334.	1.1	6
521	Genomic analysis of multiple myeloma using targeted capture sequencing in the Japanese cohort. <i>British Journal of Haematology</i> , 2020, 191, 755-763.	1.2	0
522	Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. <i>Haematologica</i> , 2020, 106, haematol.2020.247130.	1.7	16
523	Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. <i>Blood Cancer Journal</i> , 2020, 10, 70.	2.8	27
524	Proteomics-inspired precision medicine for treating and understanding multiple myeloma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 67-85.	0.4	7
525	PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	12
526	Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. <i>Clinical Cancer Research</i> , 2020, 26, 4832-4841.	3.2	33
527	Clinical prognostic implications of EPB41L4A expression in multiple myeloma. <i>Journal of Cancer</i> , 2020, 11, 619-629.	1.2	6
528	Onceâ€weekly (70 mg/m <sup>2</sup> ) vs twiceâ€weekly (56 mg/m <sup>2</sup> ) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPIONâ€ trials. <i>Cancer Medicine</i> , 2020, 9, 2989-2996.	1.3	16
529	MYC amplification on double minute chromosomes in plasma cell leukemia with double IGH/CCND1 fusion genes. <i>Cancer Genetics</i> , 2020, 242, 35-40.	0.2	2
530	Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide. <i>Cancer Medicine</i> , 2020, 9, 1694-1702.	1.3	5
531	Genomic profiling of multiple myeloma: New insights and modern technologies. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101153.	0.7	7

#	ARTICLE	IF	CITATIONS
532	Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e352-e367.	0.2	23
533	Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma. <i>Cancer Letters</i> , 2020, 475, 99-108.	3.2	22
534	Ultra-low depth sequencing of plasma cell <scp>DNA</scp> for the detection of copy number aberrations in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 465-471.	1.5	3
535	Osteoclast stimulatory transmembrane protein ( OC&#x26;STAMP ) is a promising molecular prognostic indicator for multiple myeloma. <i>European Journal of Haematology</i> , 2020, 105, 185-195.	1.1	2
536	Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. <i>Blood Advances</i> , 2020, 4, 1628-1639.	2.5	12
537	Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1810-1816.	1.3	31
538	Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies. <i>Haematologica</i> , 2021, 106, 1079-1085.	1.7	12
539	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 210-217.	1.3	7
540	Differences in safety profiles of newly approved medications for multiple myeloma in real-world settings versus randomized controlled trials. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 887-896.	0.5	6
541	Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 819-830.	3.2	6
542	Genetic Analysis of Multiple Myeloma Identifies Cytogenetic Alterations Implicated in Disease Complexity and Progression. <i>Cancers</i> , 2021, 13, 517.	1.7	12
543	A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. <i>Annals of Hematology</i> , 2021, 100, 437-443.	0.8	11
544	DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 504.	1.7	14
545	Prognostic significance of FSCN family in multiple myeloma. <i>Journal of Cancer</i> , 2021, 12, 1936-1944.	1.2	1
546	Localized Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma With Plasmacytic Differentiation. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, 939-944.	2.1	2
547	Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 161-173.	1.5	2
548	Real-world outcomes with bortezomib&#x26;containing regimens and lenalidomide plus dexamethasone for the treatment of transplant&#x26;ineligible multiple myeloma: a multi&#x26;institutional report from the Canadian Myeloma Research Group database. <i>British Journal of Haematology</i> , 2021, 193, 532-541.	1.2	9
549	Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications. <i>Cells</i> , 2021, 10, 336.	1.8	48



#	ARTICLE	IF	CITATIONS
550	Analyzing Longitudinal wb-MRI Data and Clinical Course in a Cohort of Former Smoldering Multiple Myeloma Patients: Connections between MRI Findings and Clinical Progression Patterns. <i>Cancers</i> , 2021, 13, 961.	1.7	8
552	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 3178-3189.	3.2	15
553	Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis. <i>American Journal of Hematology</i> , 2021, 96, 749-754.	2.0	3
554	Genomic characterisation of multiple myeloma: study of a Portuguese cohort. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2020-207204.	1.0	1
555	A Phase II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. <i>Bayesian Analysis</i> , 2021, 16, 179-202.	1.6	10
556	Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 243.e1-243.e6.	0.6	1
557	Multiple Myeloma: Role of Imaging in Diagnosis, Staging, and Treatment Response Assessment. <i>Seminars in Ultrasound, CT and MRI</i> , 2021, 42, 184-193.	0.7	4
558	Characteristics and outcomes of patients with multiple myeloma at the Uganda Cancer Institute. <i>African Health Sciences</i> , 2021, 21, 67-74.	0.3	4
559	Genomic Instability in Multiple Myeloma: A Non-Coding RNA Perspective. <i>Cancers</i> , 2021, 13, 2127.	1.7	8
560	The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4462.	1.8	39
561	Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma. <i>Cancers</i> , 2021, 13, 2649.	1.7	12
562	Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. <i>British Journal of Haematology</i> , 2021, 194, 120-131.	1.2	27
563	Structure and significance of cytogenetic abnormalities in patients with multiple myeloma. <i>Gematologiya I Transfuziologiya</i> , 2021, 66, 54-67.	0.1	2
564	Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. <i>European Journal of Haematology</i> , 2021, 107, 416-427.	1.1	4
565	Plasmacytoma and plasma cell myeloma affecting the jaws: A multi-institutional collaborative study. <i>Journal of Oral Pathology and Medicine</i> , 2021, 50, 613-621.	1.4	3
566	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 678-686.	1.5	2
567	Long non-coding RNA DANCR represses the viability, migration and invasion of multiple myeloma cells by sponging miR-135b-5p to target KLF9. <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	7
568	Quantification of measurable residual disease in patients with multiple myeloma based on the IMWG response criteria. <i>Scientific Reports</i> , 2021, 11, 14956.	1.6	2

#	ARTICLE	IF	CITATIONS
569	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	2.0	15
570	Genetic pathogenesis of immunoglobulin light chain amyloidosis: basic characteristics and clinical applications. <i>Experimental Hematology and Oncology</i> , 2021, 10, 43.	2.0	6
571	Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging?. <i>World Journal of Radiology</i> , 2021, 13, 223-226.	0.5	4
572	A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. <i>Cells</i> , 2021, 10, 1961.	1.8	16
573	Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	12
574	Does myeloma genetic have an effect on stem cell mobilization?. <i>Transfusion and Apheresis Science</i> , 2021, , 103249.	0.5	0
575	Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study. <i>Future Oncology</i> , 2021, 17, 4797-4812.	1.1	6
576	Effect of the uncoupling protein-2 (UCP-2) and nuclear receptor subfamily 3 group C member 1 (NR3C1) genes on treatment efficacy and survival in patients with multiple myeloma: a single-center study. <i>BMC Research Notes</i> , 2021, 14, 346.	0.6	0
577	Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. <i>European Journal of Haematology</i> , 2022, 108, 73-83.	1.1	8
578	Prognostic and predictive biomarker developments in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 151.	6.9	49
579	Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment. <i>Leukemia Research</i> , 2021, 111, 106687.	0.4	18
581	Molecular Biology Methods in the Diagnosis of Multiple Myeloma. <i>Principles and Practice</i> , 2012, , 443-449.	0.3	5
582	Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2017, 33, 303-315.	0.3	6
583	A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity. <i>HemaSphere</i> , 2020, 4, e502.	1.2	10
584	MiR-16 regulates crosstalk in NF- $\kappa$ B tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. <i>JCI Insight</i> , 2019, 4, .	2.3	33
585	GP130 activation induces myeloma and collaborates with MYC. <i>Journal of Clinical Investigation</i> , 2014, 124, 5263-5274.	3.9	34
586	Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. <i>Journal of Clinical Investigation</i> , 2016, 126, 4640-4653.	3.9	74
587	High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma. <i>Medical Science Monitor</i> , 2017, 23, 2636-2643.	0.5	4



#	ARTICLE	IF	CITATIONS
588	Characterization of Cyclin E Expression in Multiple Myeloma and Its Functional Role in Seliciclib-Induced Apoptotic Cell Death. PLoS ONE, 2012, 7, e33856.	1.1	16
589	Identification of Pluripotent and Adult Stem Cell Genes Unrelated to Cell Cycle and Associated with Poor Prognosis in Multiple Myeloma. PLoS ONE, 2012, 7, e42161.	1.1	18
590	DNA Methylation in Multiple Myeloma Is Weakly Associated with Gene Transcription. PLoS ONE, 2012, 7, e52626.	1.1	20
591	Transcriptional Repression of Bim by a Novel YY1-ReIA Complex Is Essential for the Survival and Growth of Multiple Myeloma. PLoS ONE, 2013, 8, e66121.	1.1	22
592	TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis. PLoS ONE, 2017, 12, e0174809.	1.1	19
593	Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. Forum on Immunopathological Diseases and Therapeutics, 2011, 2, 179-188.	0.1	14
594	Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism. Oncotarget, 2013, 4, 911-922.	0.8	27
595	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget, 2016, 7, 59029-59048.	0.8	16
596	Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. Oncotarget, 2017, 8, 19427-19442.	0.8	11
597	Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget, 2013, 4, 2186-2207.	0.8	145
598	A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy. Oncotarget, 2014, 5, 2487-2498.	0.8	42
599	The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. Oncotarget, 2017, 8, 58122-58132.	0.8	13
600	Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma. Oncotarget, 2018, 9, 23890-23899.	0.8	10
601	Aurora kinase and FGFR3 inhibition results in significant apoptosis in molecular subgroups of multiple myeloma. Oncotarget, 2018, 9, 34582-34594.	0.8	3
602	Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma. Oncotarget, 2015, 6, 9434-9444.	0.8	9
603	Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget, 2015, 6, 19132-19147.	0.8	41
604	Notch signaling deregulation in multiple myeloma: A rational molecular target. Oncotarget, 2015, 6, 26826-26840.	0.8	47
605	HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. Oncotarget, 2015, 6, 31134-31150.	0.8	38

#	ARTICLE	IF	CITATIONS
606	Detection of recurrent cytogenetic aberrations in multiple myeloma: A comparison between MLPA and iFISH. <i>Oncotarget</i> , 2015, 6, 34276-34287.	0.8	15
607	DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. <i>Oncotarget</i> , 2012, 3, 1246-1258.	0.8	138
608	Molecular spectrum of <i>TP53</i> mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature. <i>Oncotarget</i> , 2016, 7, 21353-21361.	0.8	40
609	Metabolic alterations and the potential for targeting metabolic pathways in the treatment of multiple myeloma. <i>Journal of Cancer Metastasis and Treatment</i> , 2019, 2019, .	0.5	28
610	Cytogenetic Abnormalities in Multiple Myeloma Patients at a Tertiary Healthcare Center in India. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 235-241.	0.5	7
611	Multiple myeloma in bisphosphonate-affected jaws—a diagnostic challenge: case report. <i>Quintessence International</i> , 2014, 45, 613-7.	0.3	3
612	Multiple Myeloma : Recent Progress in Diagnosis and Treatment. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2012, 52, 149-159.	0.3	19
613	Transient Plasmacytosis With Trisomy of Chromosome 8 in a Patient With Multiple Myeloma: A Case Report. <i>World Journal of Oncology</i> , 2013, 4, 194-200.	0.6	1
614	The Molecular Pathogenesis of Multiple Myeloma. <i>Hematology Reports</i> , 2020, 12, 9054.	0.3	9
615	Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective. <i>World Journal of Stem Cells</i> , 2020, 12, 706-720.	1.3	16
616	Treatment Approach of Nontransplant Patients with Multiple Myeloma. <i>Materia Socio-medica</i> , 2014, 26, 348.	0.3	6
617	Multiple Myeloma, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1398-1435.	2.3	55
618	13q Deletions detected by fluorescence in situ hybridization for diagnosis and prognosis of chronic lymphoproliferative neoplasms. <i>Biopolymers and Cell</i> , 2015, 31, 218-225.	0.1	2
619	No Monoclonal Protein in a Patient with CRAB Features. <i>Clinical Chemistry</i> , 2021, 67, 1584-1588.	1.5	2
620	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 75.e1-75.e7.	0.6	5
621	Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.. <i>Blood</i> , 2009, 114, 1187-1187.	0.6	0
622	Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma. <i>Blood</i> , 2010, 116, 3564-3564.	0.6	9
624	Chapter 8 The Contribution of Prognostic Factors to the Better Management of Multiple Myeloma Patients. , 0, , .		2

#	ARTICLE	IF	CITATIONS
625	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
626	The Role of Centrosomes in Multiple Myeloma. , 2012, , 255-276.		1
627	Molecular Biology and Classification of Multiple Myeloma. Principles and Practice, 2012, , 71-84.	0.3	0
628	Successful Treatment of Low-Dose Lenalidomide Maintenance Therapy Followed by Second Autologous Peripheral Blood Stem Cell Transplantation in Heavily Treated Multiple Myeloma. International Journal of Clinical Medicine, 2012, 03, 106-109.	0.1	0
629	Genetics of Multiple Myeloma. , 2013, , 1-16.		0
631	Approach to Relapsed Refractory Myeloma. , 2014, , 95-100.		0
632	Criteria for Diagnosis and Response. , 2014, , 1-15.		0
634	Molecular Classification and Risk Stratification. , 2014, , 55-64.		0
636	Routine laboratory diagnosis of chromosome aberrations in multiple myeloma. International Journal of Research in Medical Sciences, 2014, 2, 1241.	0.0	0
637	Molecular Testing in Hematologic Malignancies. , 2014, , 135-167.		1
638	Multiple Myeloma and Related Disorders. , 2014, , 1991-2017.e7.		1
639	Immunoglobulin and MYC Rearrangements in Multiple Myeloma Pathogenesis. , 2015, , 139-156.		2
640	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
641	Pooled Analysis of Pomalidomide for Treating Patients with Multiple Myeloma. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3163-3166.	0.5	2
643	Plasma Cell Myeloma. , 2016, , 6-88-6-95.		0
644	Cytogenetics: Applications. , 2016, , 67-82.		0
645	B-Cell Malignancies. , 2016, , 579-602.		3
646	Interphase Fluorescence in Situ Hybridization Analysis of Cytogenetic Abnormalities in Egyptian Patients with Plasma Cell Myeloma. Journal of Medical Science and Clinical Research, 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
648	Treatment of t(4;14) and del(17p) in Multiple Myeloma. , 2018, , 59-76.		0
649	Risk Stratification in Newly Diagnosed Transplant-Eligible Multiple Myeloma. , 2018, , 15-36.		0
650	Multiples Myelom beim alten und geriatrischen Patienten. , 2018, , 1-10.		0
651	CLINICAL, HEMATOLOGICAL CHARACTERIZATION AND POLYMORPHISM OF ABO AND Rh BLOOD GROUP SYSTEMS IN PLASMA CELL MYELOMA PATIENTS. Problemy Radiatsiinoi Medytsyny Ta Radiobiologii, 2018, 23, 410-422.	0.5	0
652	Multiples Myelom beim alten und geriatrischen Patienten. , 2018, , 261-270.		0
653	Proptosis with hemiplegia. Journal of Postgraduate Medicine, 2018, 64, 204-205.	0.2	1
654	Plasmazellneoplasien. , 2019, , 177-193.		0
655	IgL Translocations for Risk Stratification in Multiple Myeloma. , 2019, 16, .		0
657	Aberrant Epigenomic Regulatory Networks in Multiple Myeloma and Strategies for Their Targeted Reversal. RNA Technologies, 2019, , 543-572.	0.2	0
658	Aggressive Clinicopathological Course of Myeloma with t(3;16) (q21;q22) Cytogenetic Abnormality. Turkish Journal of Haematology, 2019, 36, 62-63.	0.2	0
659	Complex cytogenetic research of cryptic chromosomal aberrations in patients with multiple myeloma. , 2019, 18, 50-59.	0.3	1
660	Amplification of the <i>MYC</i> gene in immunoglobulin light chain (AL) amyloidosis. Tenri Medical Bulletin, 2019, 22, 54-62.	0.1	0
661	Small but Mightyâ€”The Emerging Role of snoRNAs in Hematological Malignancies. Non-coding RNA, 2021, 7, 68.	1.3	2
662	Multiple Myeloma in Older Adults. , 2020, , 549-565.		0
663	State of the Art for Metastatic Histologies. , 2020, , 211-233.		0
664	Plasma Cell Neoplasms (Including Plasma Cell Myeloma). , 2020, , 595-614.		0
665	Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. Oncology Research and Treatment, 2021, 44, 672-681.	0.8	25
666	<i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutations in plasma cell myeloma at a single Korean institute. Blood Research, 2020, 55, 159-168.	0.5	0

#	ARTICLE	IF	CITATIONS
667	Differential diagnosis of aggressive neoplasms with plasmablastic and late post-follicular differentiation. <i>Diagnostic Histopathology</i> , 2020, 26, 421-439.	0.2	1
668	Progress in myeloma stem cells. <i>American Journal of Blood Research</i> , 2011, 1, 135-45.	0.6	15
669	Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2014, 7, 4051-62.	1.3	5
670	The simultaneous occurrence of multiple myeloma and JAK2 positive myeloproliferative neoplasms - Report on two cases. <i>Journal of Medicine and Life</i> , 2015, 8, 55-61.	0.4	1
671	Non-secreting multiple myeloma switches to IgD of lamda type: a case report and review of literature. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 16984-90.	1.3	3
673	Methylation and mRNA expression levels of P15, death-associated protein kinase, and suppressor of cytokine signaling-1 genes in multiple myeloma. <i>Iranian Journal of Basic Medical Sciences</i> , 2016, 19, 755-62.	1.0	1
674	Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India. <i>Indian Journal of Medical Research</i> , 2016, 144, 536-543.	0.4	4
675	The Utilization of Karyotyping, iFISH, and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple Myeloma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2017, 18, 3135-3142.	0.5	1
676	LINC01234 promotes multiple myeloma progression by regulating miR-124-3p/GRB2 axis. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 6600-6618.	0.0	7
681	Cell-free DNA for genomic profiling and minimal residual disease monitoring in Myeloma- are we there yet?. <i>American Journal of Blood Research</i> , 2020, 10, 26-45.	0.6	5
682	Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma. <i>Turkish Journal of Haematology</i> , 2021, , .	0.2	0
683	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. <i>Blood Cancer Journal</i> , 2021, 11, 190.	2.8	10
684	Multiples Myelom. , 2016, , 1-17.		0
685	Molecular Profiling and Minimal Residual Disease Monitoring in Multiple Myeloma Patients: A Literature Review. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2021, 14, 436-443.	0.1	0
686	Gene expression profiling as a prognostic tool in multiple myeloma. , 2021, 4, 1008-1018.		2
687	Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. <i>American Journal of Hematology</i> , 2022, , .	2.0	5
688	Plasma Cell Neoplasia. , 2020, , 283-297.		0
689	Single-cell profiling of tumour evolution in multiple myeloma – opportunities for precision medicine. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 223-236.	12.5	58

#	ARTICLE	IF	CITATIONS
690	Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?. Hemato, 2022, 3, 63-81.	0.2	1
691	A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 21.	2.8	30
692	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission â€“ results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. BMC Cancer, 2022, 22, 147.	1.1	1
693	Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia. Clinical Lymphoma, Myeloma and Leukemia, 2022, , .	0.2	1
694	p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain). Oncogene, 2022, 41, 2106-2121.	2.6	3
695	Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma. Cells, 2022, 11, 752.	1.8	4
696	Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities. Frontiers in Oncology, 2022, 12, 805702.	1.3	3
697	Role of cytokines in multiple myeloma: IL-1RN and IL-4 VNTR polymorphisms. Cytokine, 2022, 153, 155851.	1.4	1
698	The impact of bortezomib-based induction in newly diagnosed multiple myeloma with chromosome 1q21 gain. Therapeutic Advances in Hematology, 2022, 13, 204062072210820.	1.1	3
699	Key markers for diagnosis of minimal residual disease in multiple myeloma. , 2022, 21, 42-49.	0.3	2
700	CAR T-Cell Therapy in the Older Person: Indications and Risks. Current Oncology Reports, 2022, 24, 1189-1199.	1.8	11
701	Bone marrow. , 0, , 813-942.		0
711	Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations. Cancers, 2022, 14, 2147.	1.7	2
712	Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Science, 2022, 113, 2763-2777.	1.7	11
714	Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. Journal of Clinical Oncology, 2022, 40, 3406-3418.	0.8	115
715	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	0.6	512
716	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3120-3131.	0.8	29
717	Targeting the oncogenic transcription factor c-Maf for the treatment of multiple myeloma. Cancer Letters, 2022, 543, 215791.	3.2	8

#	ARTICLE	IF	CITATIONS
718	Stratification of Patients with Multiple Myeloma: State-of-the-Art and Prospects. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2022, 15, 259-270.	0.1	1
719	Hemophagocytic lymphohistiocytosis as an onset of diffuse large B-cell lymphoma: A case report. <i>Oncology Letters</i> , 2022, 24, .	0.8	0
720	Long-Term Responders After Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
721	The Diagnostic and Treatment Challenges of Concomitant Mantle Cell Lymphoma and IgM Myeloma. <i>European Journal of Case Reports in Internal Medicine</i> , 0, , .	0.2	0
722	Myeloma and Leukemia. , 2023, , 503-528.		0
723	Multiple Myeloma Therapy: Emerging Trends and Challenges. <i>Cancers</i> , 2022, 14, 4082.	1.7	19
724	Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
725	Leukemias, Lymphomas, and Plasma Cell Disorders. , 2023, , 237-300.		0
726	Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study. <i>Integrative Cancer Therapies</i> , 2022, 21, 153473542211141.	0.8	0
727	<i>IGH</i> cytogenetic abnormalities can be detected in multiple myeloma by imaging flow cytometry. <i>Journal of Clinical Pathology</i> , 2023, 76, 763-769.	1.0	2
728	Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
729	Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma. <i>Haematologica</i> , 2023, 108, 1374-1384.	1.7	6
732	Risk Assessment for Newly Diagnosed Fit Young Patients with Multiple Myeloma in the Era of Novel Treatment Modalities: Should There Be Additional Factors Taken into Consideration??. <i>Journal of Blood Medicine</i> , 0, Volume 13, 619-630.	0.7	1
734	The Role of Epigenetics in the Development and Progression of Multiple Myeloma. <i>Biomedicines</i> , 2022, 10, 2767.	1.4	7
735	Epigenetic and genetic investigation of SOCS-1 gene in patients with multiple myeloma. <i>Blood Research</i> , 2022, 57, 250-255.	0.5	1
736	Evaluation of the Mayo Additive Staging System in patients with newly diagnosed multiple myeloma: A real-world analysis. <i>European Journal of Haematology</i> , 0, , .	1.1	0
737	VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience. <i>Annals of Hematology</i> , 0, , .	0.8	2
738	An Approach to the Diagnosis of Paraproteinemia. , 2022, , 79-97.		0

#	ARTICLE	IF	CITATIONS
739	Bioinformatics analysis of the prognostic biomarkers and predictive accuracy of differentially expressed genes in high-risk multiple myeloma based on Gene Expression Omnibus database mining. <i>Annals of Translational Medicine</i> , 2022, 10, 1325-1325.	0.7	1
740	Plasma cell neoplasms and related entitiesâ€™ evolution in diagnosis and classification. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 163-177.	1.4	17
741	Cytogenetic Abnormalities in Multiple Myeloma: Incidence, Prognostic Significance, and Geographic Heterogeneity in Indian and Western Populations. <i>Cytogenetic and Genome Research</i> , 2022, 162, 529-540.	0.6	0
742	Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2023, 30, 268-278.	1.4	6
743	A case of a Young Multiple Myeloma Patient With Poor Prognostic Cytogenetics. <i>Clinical Medicine Insights: Case Reports</i> , 2023, 16, 117954762311572.	0.3	1
744	<sc>CTN057</sc> , a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited <sc>â€MET</sc> tyrosine kinase. <i>Cancer Medicine</i> , 0, , .	1.3	1
745	Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma. <i>Cancers</i> , 2023, 15, 1558.	1.7	5
746	Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	7
747	Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma. <i>Journal of Human Genetics</i> , 2023, 68, 507-514.	1.1	4
748	Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognostic Predictors. <i>Biomedicines</i> , 2023, 11, 964.	1.4	0
749	A diagnostic approach to detect cytogenetic heterogeneity and its prognostic significance in multiple myeloma. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 1138-1147.	0.5	0
750	Progression of Hodgkin lymphoma and plasma cell neoplasms: Report from the 2021 SH/EAHP Workshop. <i>American Journal of Clinical Pathology</i> , 0, , .	0.4	0